GlassScriptPhysician profile
Candace Lynn Ryan
NPI 1538337555
$112,506.00
in general payments reported to CMS, 2019-2025
32 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,557 · 2022: $8,723 · 2023: $38K · 2024: $36K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Consulting Fee: $19K · Food and Beverage: $15K · Travel and Lodging: $14K · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,279.00 |
| Consulting Fee | $18,665.00 |
| Food and Beverage | $15,269.66 |
| Travel and Lodging | $13,795.94 |
| Education | $216.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32,783.51 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $25,132.90 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Genzyme Corporation | $19,953.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,700.74 | 2023-2025 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $8,037.94 | 2021-2025 | |
| Abbvie INC. | $3,972.66 | 2021-2025 | |
| Ucb, INC. | $2,460.42 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $2,260.63 | 2022-2025 | Otezla, Enbrel, Krystexxa |
| Pfizer INC. | $1,484.27 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $1,306.04 | 2023-2025 | Idacio |
| Janssen Biotech, INC. | $1,068.82 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $676.19 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $543.63 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $353.87 | 2022-2025 | Tymlos |
| Genentech USA, INC. | $329.16 | 2021-2025 | Actemra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $242.42 | 2022-2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $221.94 | 2023-2025 | Crysvita |
| Sanofi-Aventis U.S. LLC | $153.99 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $148.21 | 2021-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $142.30 | 2021-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $118.55 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $106.92 | 2021-2025 | Strensiq |
| Horizon Therapeutics Plc | $94.37 | 2021-2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $47.90 | 2021-2023 | Euflexxa |
| Sobi, INC | $28.40 | 2024 | |
| Sandoz INC. | $26.86 | 2023 | Hyrimoz |
| Fidia Pharma USA INC. | $25.15 | 2025 | Hymovis |
| Organon LLC | $21.70 | 2025 | Hadlima |
| Celltrion USA INC. | $18.36 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $17.62 | 2024 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $14.44 | 2023 | Truxima |
| Actelion Pharmaceuticals US, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.